Priority Date: 06.10.11 (EP 20110184061)

SUBSTITUTED BENZYLINDAZOLES FOR USE AS BUB1 KINASE INHIBITORS IN THE TREATMENT OF HYPERPROLIFERATIVE DISEASES.

  • Application ID: EP12766997
  • Status: The patent has been granted

Applicants

Technology company logo small
Technology Company

Attorney

Technology company logo thumb
no operation time available
4 offices
Technology Company

Specialization

This EP application has the IPC combination A61 (MEDICAL OR VETERINARY SCIENCE; HYGIENE) and C07 (ORGANIC CHEMISTRY). Bayer Intellectual Property GmbH is specialized in the combination A61 and C07. We found, that TransMIT GmbH, Kailuweit & Uhlemann, Lederer Keller Patentanwälte Partnerschaft mbB, Vossius & Partner Patentanwälte Rechtsanwälte mbB, df-mp Dörries Frank-Molnia & Pohlman, Patentanwälte Rechtsanwälte PartG mbB and 221 others are specialized in all of these IPC classes as well. For a similar patent, they might be a good choice.

Timeline

  • 06.10.2011 - Priority Date (EP 20110184061)
  • 11.04.2013 - Publication A1 (WO2013050438)
  • 13.08.2014 - Publication A1 (EP2763982)
  • 10.01.2018 - Publication B1 (EP2763982)